App-Quantinova.ai

A pilot study for cellular detection of circulating tumor cells and disseminated tumor cells of patients with hepatocellular carcinoma.

Nozomi Minagawa - American Society of Clinical Oncology (ASCO) , 2013

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Liver cancer

N/A

Assessment of prognosis in hepatocellular carcinoma (HCC) using biomarkers and serum measurements.

Mabel Joey Teng - American Society of Clinical Oncology (ASCO) , 2013

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Liver cancer

N/A

Phase II trial of sorafenib (S) and capecitabine (C) for hepatocellular carcinoma (HCC) in cirrhotic patients (pts).

Cristhiam Mauricio Rojas-Hernandez - American Society of Clinical Oncology (ASCO) , 2013

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Liver cancer

Capecitabine

The use of AFP and DCP as serum biomarkers to differentiate between hepatocellular carcinoma and intrahepatic cholangiocarcinoma in non-cirrhotic livers.

Ravindhi Lakmalee Nathavitharana - American Society of Clinical Oncology (ASCO) , 2013

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Advanced biliary tract carcinoma

Alfa-fetoprotein

A retrospective analysis of patients with poor-risk germ cell tumor (PRGCT) treated at Indiana University from 2000 to 2010.

Nabil Adra - American Society of Clinical Oncology (ASCO) , 2013

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Testicular cancer

N/A

Prognostic factors in patients (pts) with mediastinal nonseminomatous germ cell tumors (MNGCT).

Anatoly Bulanov - American Society of Clinical Oncology (ASCO) , 2013

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Germ cell tumor

N/A

A phase III trial of personalized chemotherapy based on serum tumor marker decline in poor-prognosis germ-cell tumors: Results of GETUG 13.

Karim Fizazi - American Society of Clinical Oncology (ASCO) , 2013

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Germ cell tumor

Oxaliplatin

Aneuploidy and neoplasia: Case of recurrent polysomy occurring at different times.

Giridhar U. Adiga - American Society of Clinical Oncology (ASCO) , 2013

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Advanced biliary tract carcinoma

Tamoxifen

Phase I trial of temsirolimus (TEM) plus sorafenib (SOR) in advanced hepatocellular carcinoma (HCC) with pharmacokinetic (PK) and biomarker correlates.

Robin Katie Kelley - American Society of Clinical Oncology (ASCO) , 2012

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Liver cancer

Temsirolimus

Efficacy, safety, tolerability, and PK of the HDAC inhibitor resminostat in sorafenib-refractory hepatocellular carcinoma (HCC): Phase II SHELTER study.

Michael Bitzer - American Society of Clinical Oncology (ASCO) , 2012

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Liver cancer

Resminostat

Bevacizumab plus temsirolimus as second-line treatment for advanced hepatocellular carcinoma (HCC).

Leonidas Chelis - American Society of Clinical Oncology (ASCO) , 2012

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Liver cancer

Temsirolimus

Serum tumor marker (STM) decline rates during high-dose chemotherapy (HDCT) to predict outcome for germ cell tumor (GCT) patients (pts).

Darren Richard Feldman - American Society of Clinical Oncology (ASCO) , 2012

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Germ cell tumor

Carboplatin

Compliance with follow-up (f.-up) program and outcome of patients (pts) with stage I nonseminomatous germ cell tumors (NSGCT).

Mikhail Fedyanin - American Society of Clinical Oncology (ASCO) , 2012

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Germ cell tumor

Cisplatin

Sorafenib in hepatocellular carcinoma (HCC): Is there a role for starting patients on a total daily dose of 400mg daily?

Olugbenga Olanrele Olowokure - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Liver cancer

Sorafenib

A phase 2 study of a novel transforming growth factor-beta (TGF-?1) receptor I kinase inhibitor, LY2157299 monohydrate (LY), in patients with advanced hepatocellular carcinoma (HCC).

Sandrine J. Faivre - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Liver cancer

LY2157299

CA19-9 as an independent risk factor for survival in hepatocellular carcinoma.

Christine Cho-Shing Hsu - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2013

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Liver cancer

N/A

Circulating biomarkers of sorafenib efficacy in advanced HCC.

Leonidas Chelis - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2013

Therapeutic Area

Disease

Drug/Treatment

N/A

Sorafenib

Association of the establishment of multidisciplinary (MDC) hepatocellular carcinoma (HCC) clinic with clinical outcome.

Adam C. Yopp - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2013

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Liver cancer

N/A

Dosimetic parameter predicting the hepatic complication after helical tomotherapy for patients with unresectable primary hepatocellular carcinoma.

Hong Seok Jang - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2012

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Liver cancer

N/A

A Giant Retroperitoneal Teratoma Post-Operative Adrenal Insufficiency

Tripti Joshi - Endocrine Society (ENDO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Congenital adrenal hyperplasia

Hydrocortisone

Filters

486 Abstracts